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Transforming growth factor alpha and epidermal growth factor levels in
bladder cancer and their relationship to epidermal growth factor receptor
JK Mellon, S Cook, P Chambers and DE Neal
Department of Urology, Freeman Hospital and Department of Surgery, University ofNewcastle upon Tyne NE2 4HH, UK.
Summary We have examined levels of epidermal growth factor (EGF) and transforming growth factor alpha
(TGF-a) in neoplastic and non-neoplastic bladder tissue using a standard radioimmunoassay technique.
Tumour samples had much higher TGF-ax levels compared with EGF and TGF-a levels in malignant tissue
were significantly higher than in benign bladder samples. There was, in addition, a difference in mean EGF
levels from 'normal' bladder samples from non-tumour bearing areas of bladder in patients with bladder cancer
compared with 'normal' bladder tissue obtained at the time of organ retrieval surgery. Levels of EGF and
TGF-c did not correlate with levels of EGF receptor (EGFR) as determined by a radioligand binding method
but levels of TGF-oc >10 ng gm of tumour tissue did correlate with EGFR positivity defined using
immunohistochemistry. These data suggest that TGF-a is the likely ligand for EGFR in bladder tumours.
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Expression of epidermal growth factor receptors (EGFRs)
may have a role in the management of transitional cell
carcinoma of the bladder, having prognostic significance in
those patients with non-muscle-infiltrative cancers (Neal et
al., 1990; Mellon et al., 1995). EGFRs found in bladder
cancers have previously been shown to be functional (Berger
et al., 1987; Smith et al., 1989) and although some studies
have assessed the effect of EGFR ligands on bladder tumour
cell lines (Messing, 1984, 1987; Momose et al., 1991;
Kawamata et al., 1993), few studies have examined for the
presence of ligands for the EGFR within the bladder tumour
itself. EGF has been examined in tumour tissue of renal and
urothelial origin as well as normal tissue using immunocy-
tochemistry (Lau et al., 1988). Typical granular staining was
noted in the cytoplasm of all transitional cell and squamous
carcinomas of the bladder. Staining of normal urothelium
was limited to superficial cells only. Subjectively, the staining
intensity of transitional cell carcinomas correlated inversely
with tumour differentiation. In view of the fact that
internalised, receptor-bound EGF is known to be rapidly
degraded, the results from this immunohistochemical study
suggest that there is active synthesis of EGF within the
cytoplasm, perhaps being involved in autocrine mechanisms
of malignant proliferation.
In an immunohistochemical study we noted that bladder
tumours with EGFR expression also stained positively for
transforming growth factor alpha (TGF-a), again consistent
with an autocrine regulation of growth (Gullick et al., 1991).
The effect ofTGF-x on bladder tumour cells has been studied
by transfecting NBT-II rat carcinoma cells with a gene
encoding human TGF-ac (Gavrilovic et al., 1990). It was
subsequently noted that the cells became motile and vimentin
positive and secreted significant levels of a 95kDa
gelatinolytic metalloproteinase. These results suggest that
expression of TGF-a in an epithelial tumour cell results in the
development of a motile, fibroblast-like phenotype with
matrix-degrading potential, which could result in a more
aggressive tumour in vivo.
Other studies have looked at EGF levels in the urine of
patients with bladder cancer. There appears to be a consensus
that the level of EGF in the urine is reduced in patients with
bladder tumours of increasing stage with levels rising again
following tumour ablation (Kristensen et al., 1988; Fuse et
al., 1992).
The objectives of this study were to quantify levels of EGF
and TGF-cx in bladder cancers by biochemical methods and
to correlate this information with EGFR levels with the aim
of determining whether EGFR ligands were present in levels
that might activate the EGFR.
Patients and methods
Seventy-four patients with newly diagnosed bladder cancer,
requiring surgical resection or biopsy, were studied.
Following cystocopy, examination under anaesthesia, tu-
mour resection and, where indicated, a computerised
tomography (CT) scan, tumours were staged by the TNM
system (Hermanek and Sobin, 1987) and graded histologi-
cally (by a single uropathologist) according to the system
described by Bergkvist et al. (1965). All conceivable measures
were taken to ensure samples contained a maximal amount of
tumour material. Representative samples of each tumour
were carefully collected in the operating theatre by the two
surgeons with a major interest in this study. For those
patients with Ta and Ti tumours, these vascular tumours
have a very high tumour-stroma ratio and very infrequently
have areas of tumour necrosis. In addition, the majority of
these superficial tumours are exophytic papillary tumours,
which are easily identifiable from adjacent tissues. For
muscle-invasive tumours necrotic tumour was deliberately
avoided when collecting samples. In addition, samples of
non-neoplastic bladder were collected from patients under-
going surgery for benign bladder pathology (n = 3) and at the
time of multiorgan retrieval surgery (n=4) as well as four
samples of 'normal' bladder collected from non-tumour-
bearing areas of bladder at the time of cystectomy for
bladder cancer. Samples of fresh, unfixed bladder tissue were
immediately frozen in liquid nitrogen. All tumour samples
and seven normal bladder samples were assayed for EGFR
and 40 tumours along with seven normal bladder samples
were assayed for EGF and TGF-oa.
Radioligand binding assay for EGFR
The essential steps of the radioligand binding assay for the
detection of EGFR have previously been reported (Sainsbury
et al., 1985; Nicholson et al., 1988; Smith et al., 1989).
Bladder tumours were analysed in triplicate using a two-point
radioligand binding assay in which a membrane suspension is
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1995incubated with 1 nM ['25I]EGF alone and in the presence of
100 nm unlabelled EGF. EGF was iodinated using the
iodogen method.
Preparation of membranes Tumour samples (approximately
0.5 g) were thawed in Tris/sodium chloride buffer (Tris
pH 7.4/50 mmolar sodium chloride) on small tin foil trays,
kept on ice. Each specimen was diced into 1-2 mm cubes,
placed in 5 ml of buffer and homogenised during 2-3 10 s
bursts in an Ultraturrax dismembrator (each burst was
interrupted by a cooling period on ice of at least 60 s). The
resultant homogenate was made up to 10 ml with buffer and
centrifuged at +4°C for 10 min at 100 g (900 r.p.m.). The
supernatant was aspirated with a Pasteur pipette and
centrifuged at +4°C for 40 min at 100 000 g (35 000 r.p.m.).
Assay for 5' nucleotidase had previously shown concentration
ofactivity in the final membrane pellet compared with the first
homogenate (Nicholson et al., 1988), indicating satisfactory
membrane preparation. The supernatant (tumour cystosol)
was decanted and stored at -70°C in preparation for
estimation of EGF and TGF-a levels by radioimmunoassay
(see below). The washed pellet was then resuspended in
approximately 3 ml ofbuffer using a glass-glass homogeniser
and stored in 1 ml aliquots at -70°C.
Two-point assay for the EGFR An aliquot of membrane
suspension was removed from the -70°C freezer and thawed.
Following determination of the protein content using the
method of Lowry (1951), the protein concentration was
adjusted to 1 mg ml-' by the addition of buffer.
Reaction tubes were incubated in a waterbath at +26°C
for 1 h. The reaction was terminated by the addition of 1 ml
of cold buffer. Samples were centrifuged for 5 min at
13 000 r.p.m. using a Microcentaur bench microcentrifuge.
After aspiration of the supernatant the membrane pellet was
washed with 0.5 ml of buffer, centrifuged for a further 5 min
and all the supernatant carefully aspirated. The radioactivity
of the pellet was then counted in a gamma-counter. Total
binding varied between 0.48% and 9.67% of total counts and
non-specific binding varied from 0.41% to 1.14% of total
counts. Specific binding was calculated by subtracting non-
specific binding from total binding.
Assay for TGF-a and EGF
Extraction of EGF/TGF-a The cytosol, i.e. the supernatant
following high-speed centrifugation, was added to twice its
volume of ice-cold ethanol (kept on ice), vortexed and
immediately centrifuged at 1250 g for 30 min at +4°C
(equivalent to 2500 r.p.m. using a Sorval RC-3B centri-
fuge). Centrifugation produced a protein residue, while EGF/
TGF-a remained soluble in the supernatant.
The supernatant was decanted into four times its volume
of ice-cold ethyl acetate and, as opposed to vortexing, this
mixture was left undisturbed at +4°C for a minimum of
16 h. Ethyl acetate allows separation of an aqueous phase
containing insoluble growth factors.
After 16 h the small aqueous phase, visible at the base of
the flask, was collected by carefully aspirating the organic
phase with a tap waterpump leaving approximately 0.5 ml in
the flask. The flask was washed with 2 x 1 ml washes of 1 M
acetic acid, collecting the washes in a small container in
preparation for lyophilisation. The contents of the container
were then frozen by dipping in liquid nitrogen, immediately
before lyophilisation in a freeze drier.
Lyophilisation ofsamples This was performed overnight in a
freeze drier (Edwards EF4 Modulyo; Temperature, -70°C,
Pressure, 0.1 atm), containing sodium hydroxide for the
adsorption of acetic acid and carbon dioxide. Once dry, the
lyophilised samples were stored at -20°C until analysed.
Radioimmunoassay for EGF and TGF-a Immediately before
analysis samples were warmed to +4°C and reconstituted in
1 ml of assay buffer (40 mM phosphate buffer, pH 7.2).
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Reconstituted samples were constantly kept on ice. The
method used for determining tissue levels of EGF and TGF-a
was similar to the method described by Gregory et al. (1989).
Optimal assay conditions were defined before the analysis of
samples (data not included). Parameters tested were: primary
antibody dilution, primary antibody incubation time,
secondary antibody incubation time, incubation temperature
and effect of different buffer solutions. In addition, the effect
of preincubation was assessed. The delayed addition of
labelled ligand to the assay system is known to improve the
ability of a radioimmunoassay to detect very low concentra-
tions of unlabelled ligand (Samols and Bilkus, 1964).
Compared with straight 24 h incubation, preincubation (of
primary antibody with unlabelled ligand) for 12 h followed
by 12 h final incubation (after addition of labelled ligand)
yielded a doubling in the assay's sensitivity without altering
the total assay time.
Known standard concentrations of ligand, used to
construct standard curves, and unknown samples were
assayed in duplicate. Aliquots of 250 ml of EGF and TGF-a
(20 pg, 50 pg, 100 pg, 250 pg, 500 pg, 750 pg, 1 ng, 5 ng and
10 ng in 250 pl of buffer) or unknown sample were pipetted
into Eppendorf tubes. To each tube was added 250 ,l ofeither
sheep anti-human EGF antibody (diluted 1:100000) or high-
affinity sheep anti-human TGF-a antibody (diluted 1: 15 000).
Known standard concentrations and unknown samples were
incubated with the primary antibodies for 12 h before the
addition of '251-labelled EGF or TGF-a (Amersham Interna-
tional). The specific activity of the radiolabelled ligands was
3000 c.p.m. pg-' or higher. On average 10-20 000 c.p.m. in
250 ,ul of buffer were added to each reaction tube. This
mixture was incubated at +4°C for a further 12 h before the
addition of 500 yl of Amerlex M donkey anti-sheep antibody
(Amersham International) followed by a final 12 h period of
incubation. At the end of a total of 36 h the samples
underwent centrifugation (Microcentaur centrifuge:
13 000 r.p.m. for 5 min). Supernatants were removed by
aspiration and the radioactivity ofthe resultant pellet counted
for 60 s in a gamma-counter. Cross-reactivity of anti-EGF
with TGF-x and anti-TGF-ac with EGF was found to be
minimal. In addition, when known amounts ofboth EGF and
TGF-a were treated exactly as tissue samples, the retrieval of
ligand was approximately 50%. The Bo (i.e. percentage
retrieval of unlabelled ligand in the absence of competition
by ['25I] ligand) was 32-60% for the EGF assay and 34-40%
for the TGF-x assay.
Results
Radioligand binding assay for EGFR
Figure 1 shows the EGFR content for tumours of different
stage and Figure 2 shows the results for tumours of different
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Figure 1 EGFR content for tumours of different stage. Mean
values in parentheses, Kruskal-Wallis test, P=0.73.
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grade. Tables I and II indicate the mean EGFR content
(±s.d.), median values and range of values for tumours of
different stage and grade respectively. Muscle-invasive
tumours had a mean EGFR of 40.6 + 73.0 fmol mg-'
compared with 14.8 + 8.4 fmol mg-' for superficial tu-
mours (Mann-Whitney test, P=0.26). On analysing the
two largest groups, there was a difference between the mean
EGFR content (fmol mg-' membrane protein) of T3
tumours (48.0 ± 87.9, n=25) compared with that of Ta
tumours (15.7 + 8.2, n=21) but this failed to reach
statistical significance (Mann-Whitney test, P=0.52). Nine
tumours contained areas of squamous metaplasia and of
these, seven had EGFR content ofgreater than 20 fmol mg-'
protein. The reproducibility of results was tested by analysing
different aliquots from nine tumours in the radioligand
binding assay. Two of these tumours had five separate
aliquots of tumour analysed with the coefficient of variation
of the result for EGFR for each being 14.5% and 23.5%.
Radioimmunoassay for EGF and TGF-a
Figure 3 shows the results of the radioimmunoassays for
EGF and TGF-a. Tumour samples had higher TGF-a levels
compared with EGF. The mean TGF-o of malignant tissue
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was 9.50 ng g-'(range: 0.34-46.43 ng g-') compared with
the mean EGF of 0.78 ng g-' (range: 0-5.40 ng mg-',
P<0.0001). Secondly, the mean TGF-a level of malignant
tissue was significantly greater than that of benign bladder
tissue, which had a mean TGF-a level of 2.60 ng g-' (range:
0.23-7.67 ng g-', P=0.016). There was, in addition, a
difference in the mean EGF levels of the four normal
bladder samples from non-tumour-bearing areas of bladder
in patients with bladder cancer (1.57 + 0.49 ng g-') com-
pared with three samples of bladder tissue obtained from
normal bladders at the time of organ retrieval surgery
(0.40 + 0.27 ng g-', P=0.05). This difference must be
interpreted with some caution as such low EGF levels are
derived using the extreme left of the standard curve for EGF
and are, therefore, prone to error. There was no statistical
difference in the mean TGF-a content of normal bladder
tissue from bladder cancer patients (3.17 + 3.04 ng g-')
compared with samples obtained at organ retrieval
(1.87 +1.77 ng g-, P=0.86); the mean EGF compared
with TGF-ax in benign samples (P=0.15); or the levels of
EGF in benign compared with malignant samples (P=0.17).
Table III shows the mean levels of TGF-oc and EGF for
tumours of different stage. TGF-a levels were greater in all
categories of tumour compared with normal bladder tissue,
however, there was no significant difference between the levels
of TGF-oc for tumours of different stage (P=0.133).
Comparable levels of EGF were found in both benign and
malignant bladder specimens.
TGF-a/EGF and EGFR There was no relationship between
TGF-a levels and EGF levels (Figure 4). Nor was there a
relationship between EGF levels and EGFR (Figure 5) or
between TGF-a levels and EGFR content (Figure 6) when
comparing results from the radioimmunoassay for EGF/
TGF-a with results from the radioligand binding assay for
EGFR. However, the majority of tumours (n= 32) were also
assessed for EGFR using an immunohistochemical method
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Figure 2 EGFR content for tumours of different grade. Mean
values in parentheses. G1/2 vs G3: P=0.62.
Table I EGFR content and tumour stage
EGFR content
Tumour stage (fmol mg-'protein) Range Median
Normal/benign 13.7i9.8 5.2-32.8 11.7
bladder lesions
(n= 7)
Ta(n=21) 15.7±8.2 3.8-29.1 15.5
Tal(n= 15) 13.7+ 8.8 2.8-33.6 14.0
T2(n =8) 27.0± 28.5 5.0-89.8 13.8
T3(n =25) 48.0 + 87.9 0.01-340.0 12.5
T4(n = 5) 25.2 + 22.8 4.0-54.0 20.0
Kruskal-Wallis analysis of variance (excluding T4 tumours),
P= 0.73.
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Figure 3 EGF/TGF-ae levels in bladder specimens. Mean values
in parentheses. *, EGF; 0, TGF-aC.
Table II EGFR content and tumour grade
EGFR content
Tumour grade (fmolmg-1 protein) Range Median
Grade 1 (n =4) 18.1 +5.6 10.0-22.9 19.8
Grade 2 (n=31) 15.7±10.3 3.8-48.0 14.0
Grade 3 (n=39) 38.9±72.4 0.01-340.0 13.6
Mann - Whitney test (G1/2 vs G3), P=0.62.
Table III Mean levels of EGF and TGF-a for tumours of different
stage (ng g )
N Ta Ti T2 T3 T4
n=7 n=12 n=5 n=6 n=16 n=l
Mean TGF-cx 2.60 11.83 9.66 7.97 8.60 4.55
Mean EGF 1.07 0.85 1.36 0.71 0.61 0.63
One-way analysis ofvariance comparing TGF-a with tumour stage,
P=0.133. One-way analysis ofvariance comparing EGF with tumour
stage, P= 0.385. N, normal bladder.
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and the monoclonal antibody EGFR1 (Wright et al., 1991).
There was a positive correlation between EGFR positivity as
defined by immunohistochemistry and a TGF-ax level of
greater than 10 ng g-' of tumour tissue (Table IV).
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Epidermal growth factor receptors have been studied in
several tumours with variable results in terms ofprognosis. In
a large study reported recently of the prognostic role of
epidermal growth factor receptors in breast cancer, expres-
sion ofepidermal growth factor receptors was associated with
.* reduced relapse-free survival and overall survival in node-
* . | negative patients but did not have the same effect on the
2.4 3.6 4.8 6.0 study group as a whole (Fox et al., 1994). Although several
EGF (ng g1) previous studies have reported the presence of apparently
functional EGF receptors in bladder tumours, there have
between TGF-a and EGF. Bladder been few previous studies to indicate the presence of tissue
-0.11, P, not significant. ligands that might be responsible for EGF receptor activation
in these tumours.
One characteristic of the study population that differs
from that expected if dealing with a randomly selected group
of patients with newly diagnosed bladder cancer is that there
was a relatively high proportion of muscle-invasive tumours
in the study group. It is probable that this anomaly is the
result of only tumours that were sufficiently large to provide
samples for both routine histopathology and for snap
freezing being included in the study.
TGF-a correlated with EGFR based on immunohisto-
chemical but not biochemical detection. In comparing the
results of the two different methods of assessing EGFR,
tumours were defined as EGFR positive on radioligand
* binding when the EGFR content exceeded 20 fmol mg-'.
Agreement between the two methods was found in 63 cases
(42 doubly negative and 21 doubly positive), giving an overall
. . concordance rate of 85%. When the results of the two
| | | 11.......t methods did not agree, it is of interest that 8 of 11 tumours
50 60 70 80 90 100 330 340 had EGFR in the range 10-30 fmol mg-I and could
EGFR (fmol mg-1) therefore be classified as borderline on the radioligand
binding assay. The discrepant cases could be divided into
between EGF and EGFR. Bladder two broad categories: six pTa tumours, of which five were
-0.003, P, not significant. defined as EGFR positive on ligand binding but negative on
immunohistochemistry, and five muscle-invasive tumours, of
which the converse was true. A possible explanation of these
differences in muscle-invasive tumours is that the tissue
samples included a variable amount of necrotic tumour or
contamination of the tumour sample with stromal elements
of low EGFR content. Neal et al. (1989) have previously
observed differences in the two detection methods, especially
for tumours that are not invading the bladder muscle
(pTa + pTl) and commented that ligand binding appeared
more sensitive in the detection of EGFR in tumours
containing low to moderate amounts of receptor. The
finding of a lack of correlation between TGF-a levels and
* 0 EGFR content using biochemical methods may not be
altogether surprising and is possibly explained by receptor-
ligand interaction causing down-regulation of the receptor in
* the presence ofhigh ligand concentration. The very low levels
IL 11 of EGF found in all the specimens analysed makes
50 60 70 80 90 100 330340 correlation with TGF-ax levels and EGFR content imprecise.
;FR (fmol mg1) These data indicating significant levels of TGF-a with
barely detectable levels of EGF in bladder cancer are in
between TGF-a and EGFR. Bladder keeping with the data reported by Gregory et al. (1989) in a
.005, P, not significant. series of breast cancers. Such data reinforce the theory that
TGF-a is the more important ligand for the EGFR at tissue
level, where it acts in an autocrine/paracrine mode, whereas
Lnd EGFR positivity using immunohisto- EGF behaves predominantly in an endocrine fashion (Velu,
hemistry (n =32) 1990). Although TGF-a could be detected in both benign and
TGF-a level malignant bladder specimens, there were significantly higher
<10 ngg-I >10 ng g-I levels in the latter. The finding of similar levels of TGF-ax in
superficial compared with muscle-invasive tumours is of
157 6 interest. One theory that might explain this is that TGF-a
may have a role in promotion of angiogenesis in relatively
05. vascular superficial tumours.
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Attempts have been made by workers in other institutions
to exploit EGF receptor overexpression by certain tumours
by conjugating cytotoxic agents with EGF or TGF-a
(Chaudhary et al., 1987; Sarosdy et al., 1992). Conjugation
of such agents with receptor ligand rather than with large
monoclonal antibodies to the receptor has a theoretical
advantage in that tumour tissue penetration should be better.
Most recently a hybrid protein (TP-40) consisting of TGF-a
fused to a segment of pseudomonas exotoxin-A protein has
been shown to selectively bind tissues rich in EGFR. In
studies using the bladder carcinoma cell lines, 5637, J82,
RT4, Scaber, T-24, MBT-2 and TCC-SUP, TP-40 has been
shown to have a significant growth-inhibitory effect (Sarosdy
et al., 1993).
Acknowledgements
Kilian Mellon was supported by the Northern Counties Kidney
Research Fund. We are grateful to the North of England Cancer
Research Campaign, which funded this study, and to ICI,
Macclesfield, UK, which supplied the EGF and TGF-a with
corresponding antibodies. Dr MC Robinson in the Department of
Pathology, Freeman Hospital, graded all the tumours.
References
BERGER MS, GREENFIELD C, GULLICK WJ, HALEY J, DOWN-
WARD J, NEAL DE, HARRIS AL AND WATERFIELD MD. (1987).
Evaluation of epidermal growth factor receptors in bladder
tumours. Br. J. Cancer, 56, 533-537.
BERGKVIST A, LJUNGQVIST A AND MOBERGER G. (1965).
Classification of bladder tumours based on the cellular pattern.
Acta Chir. Scand., 130, 371-378.
CHAUDHARY VK, FITZGERALD DJ, ADHYA S AND PASTAN I.
(1987). Activity of a recombinant fusion protein between
transforming growth factor type alpha and Pseudomonas toxin.
Proc. Natl Acad. Sci. USA, 84, 4538-4542.
FOX SB, SMITH K, HOLLYER J, GREENALL M, HASTRICH D AND
HARRIS AL. (1994). The epidermal growth factor receptor as a
prognostic marker: results of 370 patients and review of 3009
patients. Breast Cancer Res. Treat., 29, 41-49.
FUSE H, MIZUNO I, SAKAMOTO M AND KATAYAMA T. (1992).
Epidermal growth factor in urine from thepatients with urothelial
tumours. Urol. Int., 48, 261-264.
GAVRILOVIC J, MOENS J, THIERY JP AND JOUANNEAU J. (1990).
Expression of transfected transforming growth factor alpha
induces a motile fibroblast-like phenotype with extracellular
matrix-degrading potential in a rat bladder carcinoma cell line.
Cell Regulation, 1, 1003- 1014.
GREGORY H, THOMAS CE, WILLSHIRE IR, YOUNGJA, ANDERSON
H, BAILDAM A AND HOWELL A. (1989). Epidermal and
transforming growth factor a in patients with breast tumours.
Br. J. Cancer, 59, 605-609.
GULLICK WJ, HUGHES CM, MELLON K, NEAL DE AND LEMOINE
NR. (1991). Immunohistochemical detection of the epidermal
growth factor receptor in paraffin-embedded human tissues. J.
Pathol., 164, 285-289.
HERMANEK P AND SOBIN LH. (1987). TNM Classification of
Malignant Tumours, 4th edn, pp.133. Springer: New York.
KAWAMATA H, KAMEYAMA S, NAN L, KAWAI K AND OYASU R.
(1993). Effect of epidermal growth factor and transforming
growth factor beta 1 on growth and invasive potentials of newly
established rat bladder carcinoma cell lines. Int. J. Cancer, 55,
968-973.
KRISTENSEN JK, LOSE G, LUND F AND NEXO E. (1988). Epidermal
growth factor in urine from patients with urinary bladder
tumours. Eur. Urol., 14, 313-314.
LAU JL, FOWLER JE Jr AND GHOSH L. (1988). Epidermal growth
factor in the normal and neoplastic kidney and bladder. J. Urol.,
139, 170-175.
LOWRY OH, ROSEBROUGH NJ, FARR AL AND RANDALL RJ.
(1951). Protein measurement with the Folin phenol reagent. J.
Biol. Chem., 193, 265-275.
MELLON K, WRIGHT C, KELLY P, HORNE CHW AND NEAL DE.
(1995). Long-term outcome related to EGFR status in bladder
cancer. J. Urol., 153, 919-925.
MESSING E. (1984). Growth factors and human bladder tumors. J.
Urol., 131, lllA.
MESSING EM, HANSON P, ULRICH P AND ERTURK E. (1987).
Epidermal growth factor-interactions with normal and malig-
nant urothelium in vivo and in situ studies. J. Urol. 138, 1329-
1335.
MOMOSE H, KAKINUMA H, SHARIFF SY, MITCHELL GB, RADE-
MAKER A AND OYASU R. (1991). Tumor-promoting effect of
urinary epidermal growth factor in rat urinary bladder
carcinogenesis. Cancer Res., 51, 5487-5490.
NEAL DE, SMITH K, FENNELLY J, BENNETT MK, HALL RR AND
HARRIS AL. (1989). The epidermal growth factor receptor in
human bladder cancer: a comparison of immunohistochemistry
and radioligand binding. J. Urol., 141, 517-521.
NEAL DE, SHARPLES L, SMITH K, FENNELLY J, HALL RR AND
HARRISAL. (1990). The epidermal growth factor receptor and the
prognosis of bladder cancer. Cancer, 65, 1619-1625.
NICHOLSON S, SAINSBURY JRC, NEEDHAM GK, CHAMBERS P,
FARNDON JR AND HARRIS AL. (1988). Quantitative assays of
epidermal growth factor receptor in human breast cancer: cut-off
points ofclinical relevance. Int. J. Cancer, 42, 36-41.
SAINSBURY JRC, SHERBERT GV, FARNDON JR AND HARRIS AL.
(1985). Epidermal-growth-factor receptors and oestrogen recep-
tors in human breast cancer. Lancet, 1, 364-366.
SAMOLS E AND BILKUS D. (1964). A comparison of insulin
immunoassays. Proc. Soc. Exp. Biol. Med., 115, 79-84.
SAROSDY MF, HUTZLER D AND VON HOFF DD. (1992). TP-40 in
bladder cancer: A hybrid protein with selective targeting and
cytotoxicity. J. Urol., 147, (supplo), 261A.
SAROSDY MF, HUTZLER DH, YEE D AND VON HOFF DD. (1993). In
vitro sensitivity testing ofhuman bladder cancers and cell lines to
TP-40, a hybrid protein with selective targeting and cytotoxicity.
J. Urol., 150, 1950- 1955.
SMITH K, FENNELLY JA, NEAL DE, HALL RR AND HARRIS AL.
(1989). The epidermal growth factor in human bladder cancer:
characterization and quantitation ofthe epidermal growth factor
in invasive and superficial bladder tumors. Cancer Res., 49,
5810-5815.
VELU TJ. (1990). Stucture, function and transforming potential of
the epidermal growth factor receptor. Mol. Cell. Endocrinol., 70,
205-216.
WRIGHT C, MELLON K, JOHNSTON P, LANE DP, HARRIS AL,
HORNE CHW AND NEAL DE. (1991). Expression ofmutant p53,
EGFR and c-erbB-2 in transitional cell carcinoma of the human
urinary bladder. Br. J. Cancer, 63, 967-970.